## Taro Yamashita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4015940/publications.pdf

Version: 2024-02-01

86 papers

5,164 citations

201385 27 h-index 70 g-index

89 all docs 89 docs citations

89 times ranked 6735 citing authors

#	Article	IF	CITATIONS
1	EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology, 2009, 136, 1012-1024.e4.	0.6	1,029
2	EpCAM and $\hat{l}_{\pm}$ -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Research, 2008, 68, 1451-1461.	0.4	689
3	Cancer stem cells in the development of liver cancer. Journal of Clinical Investigation, 2013, 123, 1911-1918.	3.9	452
4	Activation of Hepatic Stem Cell Marker EpCAM by Wnt‑β-Catenin Signaling in Hepatocellular Carcinoma. Cancer Research, 2007, 67, 10831-10839.	0.4	405
5	Discrete nature of EpCAM <sup>+</sup> and CD90 <sup>+</sup> cancer stem cells in human hepatocellular carcinoma. Hepatology, 2013, 57, 1484-1497.	3.6	241
6	The evolving concept of liver cancer stem cells. Molecular Cancer, 2017, 16, 4.	7.9	181
7	Molecular Biology of Liver Cancer Stem Cells. Liver Cancer, 2014, 3, 71-84.	4.2	146
8	Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 100-110.	1.8	141
9	The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 127-134.	1.8	124
10	Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology, 2014, 60, 1674-1685.	3.6	104
11	Oncostatin M Renders Epithelial Cell Adhesion Molecule–Positive Liver Cancer Stem Cells Sensitive to 5-Fluorouracil by Inducing Hepatocytic Differentiation. Cancer Research, 2010, 70, 4687-4697.	0.4	88
12	Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biology, 2019, 20, 252.	3.8	78
13	Comprehensive Gene Expression Profile of a Normal Human Liver. Biochemical and Biophysical Research Communications, 2000, 269, 110-116.	1.0	77
14	Hepatocellular Carcinoma with $\hat{I}^2$ -Catenin Mutation: Imaging and Pathologic Characteristics. Radiology, 2015, 275, 708-717.	3.6	74
15	Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. Journal of Hepatology, 2008, 49, 207-216.	1.8	70
16	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. PLoS ONE, 2014, 9, e84807.	1.1	70
17	Postâ€progression survival and progressionâ€free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatology Research, 2016, 46, 650-656.	1.8	66
18	Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis., 2020, 8, e001367.		62

#	Article	IF	CITATIONS
19	Characteristics of Immune Response to Tumorâ€Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. Hepatology, 2019, 69, 653-665.	3.6	56
20	Identification of microRNAs specific for epithelial cell adhesion molecule–positive tumor cells in hepatocellular carcinoma. Hepatology, 2015, 62, 829-840.	3.6	51
21	Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. Journal of Gastroenterology, 2014, 49, 1105-1110.	2.3	40
22	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatology Research, 2015, 45, 949-959.	1.8	40
23	Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. Hepatology Research, 2018, 48, 956-966.	1.8	39
24	CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nature Communications, 2020, 11, 1557.	5.8	38
25	Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatology Research, 2020, 50, 871-884.	1.8	35
26	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. Journal of Gastroenterology, 2021, 56, 67-77.	2.3	34
27	A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM. Journal of Molecular Evolution, 2015, 81, 210-217.	0.8	33
28	Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 960-964.	1.4	30
29	Gadoxetic acidâ€enhanced magnetic resonance imaging reflects coâ€activation of βâ€catenin and hepatocyte nuclear factor 4α in hepatocellular carcinoma. Hepatology Research, 2018, 48, 205-216.	1.8	28
30	Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. PLoS ONE, 2017, 12, e0188549.	1.1	27
31	Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection. Hepatology, 2019, 70, 25-39.	3.6	26
32	Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nature Cancer, 2021, 2, 1039-1054.	5.7	26
33	Severe Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Deceased-donor and Living-donor Liver Transplantation. Transplantation Proceedings, 2014, 46, 3523-3535.	0.3	25
34	Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase $1$ expression in vitro and in vivo. Scientific Reports, 2017, 7, 16978.	1.6	25
35	Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. BMC Cancer, 2017, 17, 870.	1.1	25
36	Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90. Scientific Reports, 2017, 7, 11292.	1.6	24

3

#	Article	IF	Citations
37	Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 236-249.	4.2	24
38	Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. BMC Cancer, 2015, 15, 260.	1.1	22
39	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child–Pugh B cirrhosis. Cancer Science, 2016, 107, 1263-1269.	1.7	22
40	Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Liver Cancer, 2019, 8, 130-139.	4.2	21
41	Serum Laminin $\hat{I}^3$ 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. Hepatology, 2021, 74, 760-775.	3.6	21
42	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. Journal of Gastroenterology, 2022, 57, 120-132.	2.3	20
43	Adipose tissueâ€derived stem cells prevent fibrosis in murine steatohepatitis by suppressing ILâ€17â€mediated inflammation. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1432-1440.	1.4	18
44	Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. Journal of Gastroenterology, 2018, 53, 740-751.	2.3	17
45	Development of novel diagnostic system for pancreatic cancer, including early stages, measuring <scp>mRNA</scp> of whole blood cells. Cancer Science, 2019, 110, 1364-1388.	1.7	17
46	Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. Translational Oncology, 2020, 13, 100777.	1.7	17
47	Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. Journal of Gastroenterology, 2020, 55, 701-711.	2.3	16
48	De Novo Emergence of Mesenchymal Stem-Like CD105 + Cancer Cells by Cytotoxic Agents in Human Hepatocellular Carcinoma. Translational Oncology, 2017, 10, 184-189.	1.7	14
49	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 269-285.	2.3	14
50	BMP9â€ID1 signaling promotes EpCAMâ€positive cancer stem cell properties in hepatocellular carcinoma. Molecular Oncology, 2021, 15, 2203-2218.	2.1	14
51	BMP9-ID1 Signaling Activates HIF- $1\hat{l}\pm$ and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 1475.	1.8	14
52	Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2022, 23, 2801.	1.8	13
53	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer, 2016, 16, 338.	1.1	12
54	Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. Regenerative Therapy, 2021, 18, 97-101.	1.4	12

#	Article	IF	CITATIONS
55	Distinct chemotherapyâ€associated antiâ€cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Cancer Science, 2019, 110, 903-912.	1.7	11
56	Liver cancer stem cells: Recent progress in basic and clinical research. Regenerative Therapy, 2021, 17, 34-37.	1.4	11
57	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. Cytotherapy, 2021, 23, 137-145.	0.3	10
58	Expression of Cancer Stem Cell Markers EpCAM and CD90 Is Correlated with Anti- and Pro-Oncogenic EphA2 Signaling in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 8652.	1.8	10
59	Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. Hepatology Research, 2021, 51, 190-200.	1.8	9
60	DOCK11 and DENND2A play pivotal roles in the maintenance of hepatitis B virus in host cells. PLoS ONE, 2021, 16, e0246313.	1.1	8
61	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nature Communications, 2022, $13$ , .	5.8	8
62	Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab. Clinical Journal of Gastroenterology, 2020, 13, 935-939.	0.4	7
63	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. PLoS ONE, 2020, 15, e0232089.	1.1	7
64	The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients. Hepatology International, 2021, 15, 695-706.	1.9	7
65	Phosphorylation of <scp>hTERT</scp> at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs. Journal of Pathology, 2022, 257, 172-185.	2.1	7
66	Stemness of liver cancer: From hepatitis B virus to Wnt activation. Journal of Hepatology, 2016, 65, 873-875.	1.8	6
67	A novel α-fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma. Scientific Reports, 2020, 10, 4021.	1.6	6
68	Interdisciplinary groups perform better than intradisciplinary groups in online group discussion activities. Medical Education Online, 2021, 26, 1886649.	1.1	6
69	Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. Stem Cell Research, 2021, 54, 102425.	0.3	6
70	Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial. JMIR Research Protocols, 2020, 9, e17904.	0.5	6
71	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver. Liver Cancer, 2020, 9, 261-274.	4.2	5
72	Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma. Cancer Cell International, 2017, 17, 94.	1.8	4

#	Article	IF	CITATIONS
73	Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clinical Journal of Gastroenterology, 2019, 12, 63-70.	0.4	4
74	Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. American Journal of Cancer Research, 2021, 11, 3163-3175.	1.4	4
75	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. Cancer Medicine, 2020, 9, 4907-4917.	1.3	2
76	ILâ€28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1813-1820.	1.4	2
77	Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. Regenerative Therapy, 2021, 18, 497-507.	1.4	2
78	Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients. Journal of Clinical Medicine, 2022, 11, 3870.	1.0	2
79	Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice. Scientific Reports, 2021, 11, 13021.	1.6	1
80	Oral Corticosteroids Impair Mucin Production and Alter the Posttransplantation Microbiota in the Gut. Digestion, 2022, 103, 269-286.	1.2	1
81	A case of traumatic diaphragmatic hernia that caused obstruction of middle hepatic vein. Acta Hepatologica Japonica, 2021, 62, 413-419.	0.0	O
82	Surrogacy of time to prgression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials Journal of Clinical Oncology, 2018, 36, 403-403.	0.8	0
83	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis., 2020, 15, e0232089.		О
84	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis., 2020, 15, e0232089.		0
85	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis., 2020, 15, e0232089.		0
86	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis., 2020, 15, e0232089.		O